Cell Geoffrey R Oxnard
GRACEcastUC-038_Lung_Managing Acq. Resistance to EGFR Therapy (and Probably Crizotinib, Too) Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, outlines how useful cell-free DNA sequencing will be in the Association Between Plasma Genotyping and Outcomes of Geoffrey Oxnard, MD, on the effectiveness of lorlatinib as a frontline agent in ALK+ NSCLC Geoffrey R. Oxnard, MD, assistant professor of Medicine, Dana-Farber Cancer Center, Harvard Medical School, discusses a study Geoffrey Oxnard, MD, a thoracic oncologist at Dana-Farber Cancer Institute, led research showing Liquid Biopsy can accurately ...